Epinephrine infusion causes variable increases in the components of the Factor VIII (antihemophilic factor) complex in patients with von Willebrand's disease. The increase in antihemophilic factor procoagulant activity was greater than that of Factor VIII-related antigen and von Willebrand factor activity in two patients with von Willebrand's disease. Similar increases in the three individual factors were demonstrated in two other patients. A 4-10-fold increase in Factor VIII-related properties was identified in each of these individuals after infusion. One patient has been studied with very severe von Willebrand's disease; none of the Factor VIII-related properties increased despite two infusions of epinephrine. Bleeding times were normalized or remained normal in the two patients whose von Willebrand factor activity was greater than 25 U/100 ml. It remained prolonged in those three patients whose von Willebrand factor activity levels remained below that concentration. The increase in procoagulant activity was transient in all patients and t 1/2 values were estimated to be between 0.8 and 3.4 h.
INTRODUCTION Most patients with von Willebrand's disease (VWD)'
have reduced plasma levels of antihemophilic factor proThis work was presented in part at the 17th Annual Meeting of the American Society of Hematology, Atlanta, Ga., 1 December, 1974 , and appeared in abstract form in Blood. 44: 907. 1974 .
Received for publication 27 September 1975 and in revised form 27 January 1976. 'Abbreviations used in this paper: Factor VIII (antihemophilic factor, AHF), general term for the plasma protein; VIIIAGN, antigen which precipitates with rabbit antibody prepared against human factor VIII; VIIIA3F. clotcoagulant activity (VIIIAHF), antihemophilic factor antigen (VIIIAGN), and von Willebrand factor activity (VIIIvwF) (1) . In addition, patients with VWD generally manifest abnormal bleeding times, diminished retention of their platelets to glass bead filters, and a characteristic delayed response to transfusion with plasma or antihemophilic factor (Factor VIII) concentrates (2-7).
Although it has both practical and conceptual importance, the cause of the sustained rise in VIIIAJI after transfusion in VWD, greater than that calculated from the quantity of VIIIAHF transfused, is not understood (4) (5) (6) (7) . Previous studies have suggested that this posttransfusion VIIIAHF has physicochemical (8) and procoagulant (4) (5) (6) (7) properties like those of normal plasma Factor VIII. While susceptible to inactivation by both human and rabbit anti-Factor VIII antibodies (9) , it has been reported that the "stimulated Factor VIII" does not precipitate with rabbit anti-Factor VIII (9, 10) , an observation which suggests an incomplete Factor VIII may be produced in these patients. Studies in our laboratory (11) and elsewhere (10, 12, 13) , have shown variable responses after transfusion of plasma or cryoprecipitate in these patients, however; these differences may reflect differences in the nature (7) . Informed consent was obtained from all patients and the protocol was approved by the human experimentation committees of both medical centers.
Patients were sedated with 100 mg of secobarbital the evening before the study. All blood samples were obtained with the patients in the supine position utilizing a no. 19 gauge scalp vein needle and polypropylene syringe. A slow infusion of 5% dextrose in water was maintained through the needle to keep it patent and 7 ml of blood-glucose solution was discarded before drawing each specimen.
Epinephrine hydrochloride (Parke, Davis and Co., Detroit, Mich.) in 23.4-77 ml of 0.9% saline, a total dose of 0.0042 mg/kg, was infused at a constant rate by infusion pump (Harvard Apparatus Co., Inc., Millis, Mass.) over 30 min. A mean pulse rate increase of 33 beats/min was observed and systolic pressure increased 38 mm Hg. Cardiac rhythm was monitored throughout the experiment and symptoms were limited to mild anxiety, palpitations, and peripheral vasoconstriction. A brief period of atrial-ventricular dissociation was noted in one patient (H. E.) but disappeared immediately upon discontinuation of the infusion. No other dysrhythmias were noted.
Blood was collected into a buffered citrate solution containing 0.1 M sodium citrate (three parts) and 0.1 M citric acid (two parts) with a pH of 5.1 (nine parts blood: one part anticoagulant) in polypropylene tubes (Falcon Plastics, Oxnard, Calif.) and immediately centrifuged (12,500 g) at 4VC for 20 min. Citrated plasma was assayed immediately for VIIIAHF by a modification of the one stage activated partial thromboplastin time assay (27) (28) . Sample plasmas for other assays were frozen immediately in dry ice and acetone and stored at -70'C. VIIIAGN and VIIIvwF were determined on frozen samples by radioimmunoassay (29) and the washed platelet-ristocetin (Abbott Laboratories, North Chicago, Ill.) assay (1) . Bleeding times were determined by the method of Mielke et al. (30) ; the normal range in our laboratory is 2-6 min. Plasma samples containing the postinfusion peak VIIIAHF levels were chromatographed on 6%o agarose (Bio-Gel A5M, Bio-Rad Laboratories, Richmond, Calif.) using a 1.6 X 28-cm column (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) at an elution rate of 20 ml/h. 2-ml fractions were collected using barbital-saline (7.3 g NaCl, 2 .76 g barbital, 2 .06 g Na barbital/liter, pH 6.8) as the eluting buffer. VIIIAHF in column fractions was determined by the method of Breckenridge and Ratnoff (31) . All assays of the Factor VIII properties (VIIIAHF, VIIIAGN, VIIIvwF) are expressed as units/100 ml. A frozen pool prepared from plasmas from 20 individuals with no history of bleeding disorders was used as standard in these studies and is designated as having 100 U/100 ml of each property.
The sucrose density gradient methods have been described (32) . Briefly, 13.5 ml continuous 10-40% sucrose density gradients were prepared in imidazole-saline (0.02 M imidazole, 0.14 M NaCl, pH 7.4). Whole plasma (0.75 ml) was applied to gradients which were centrifuged for 27 h at 201,800 g at 4VC using an SW 40 head. Recovery of VIIIAHF and VIIIAGN exceeded 75%. Samples were assayed for VIIIAKF at 1: 6 dilutions or greater (32) . Table I summarizes the clinical and laboratory features of the five patients who have been studied. One patient (W. H.) had mild clinical bleeding with only a modest increase in bleeding after surgical challenge. Three (D. K., M. H., and C. P.) had evidence of moderate clinical bleeding (epistaxis, menometrorrhagia, and transfusions after minor surgical procedures) and one (H. E.) had clinically severe bleeding (spontaneous hemarthroses). Except in H. E., the severity of the bleeding disorder did not correlate well with the levels of the several components of the Factor VIII complex.
RES ULTS
The response to epinephrine infusion was similar in patients W. H. (Fig. 1) and D. K. (Fig. 2 ). Somewhat greater increase in VIIIAHF than in VIIIAGN or VIIIvwF was noted after epinephrine infusion in patients M. H. (Fig. 3 ) and C. P. (Fig. 4) , both of whom had equivalent levels of VIIIAHY and VIIIAGN before epi- nephrine infusion. C. P. (Fig. 4) M. H. and no other determinations were carried out. The bleeding time remained longer than 20 min in C. P. Patient H. E. (Fig. 5) , whose VIIIAGN level was less than 1 U/100 ml, was the most severely affected patient tested. No changes in VIIIAHF, VIIIAGN, or VIIIvwF could be detected after two separate epinephrine infusions and the bleeding time remained long (greater than 20 min).
An estimate of the molecular size of the "stimulated VIIIAHF" was obtained by agarose gel chromatography and sucrose density gradient ultracentrifugation of plasma samples stored at -70'C for 2-8 wk. Fig. 6 illustrates the chromatographic patterns found on the peak postepinephrine infusion samples of patients W. H. and D. K. Both VJIIAIHR and VJIIAGN were eluted in the void volume fractions indicating a molecular weight of greater than 1.0 X 106 daltons. This elution pattern is the same as that previously reported for normal plasma VIIIAHF (33) . A preliminary sucrose density centrifugation study has also been carried out with a postepinephrine infusion sample of patient D. K. The "stimulated VIIIAHF" was found in the same fractions as VIIIAHRF in normal plasma, i.e. fractions which correspond to molecular weight of greater than 1.0 X 10' (32).
DISCUSSION
The response to transfusion of patients with VWD has intrigued observers since the initial description by Nilsson and co-workers in 1959 (4). Despite variability in response to transfused plasma among some patients with VWD (34), and a degree of overlap with normal individuals (35), the delayed peak and slower disap- (38, 39) , and the detection of both VIIIAGN and VIIIVwF in the media of cultured human endothelial cells (40, 41) , suggests that the rapid effect of epinephrine may be due to Factor VIII release from endothelial cells. This interpretation is supported by the identification of VIIIAGN in endothelial cells of superficial veins obtained by biopsy in patients with mild or moderate VWD (42) . The failure to detect an epinephrine effect in patient H. E. is also consistent with this hypothesis, for VIIIAGN was not detected in endothelial cells of patients with severe VWD (42) . Based on these studies, it is conceivable that pharmacologic manipulation of Factor VIII release may be accomplished in the future without supplying exogenous plasma proteins. Long acting vasoactive drugs may be useful in the support of patients with VWD during short term surgical procedures or in the management of limited trauma. Further investigation of the mechanism of the in vivo response of Factor VIII to pharmacologic agents seems warranted. The bleeding time remained prolonged in two of the patients studied (W. H. and C. P.) even though VIIIAHF, VIIIAGN, and VIIIvwi levels were increased after epinephrine infusion. Previous studies of the relationship of the bleeding time to VIIIvwF suggest that a normal bleeding time indicates VIIIvwF levels above a critical value estimated to be between 20 and 40 U/100 ml (1, 43) . The VIIIvwF (and VIIIAGN) levels remained below 25 U/100 ml during the postinfusion period in both W. H. and C. P.; the persistently prolonged bleeding time in these patients is consistent with previous studies of this relationship (1, 43) . In contrast, the bleeding time shortened from 10 to 4 min after epinephrine infusion in D. K. as the VIIIVwF level rose to 32 U/100 ml. The correlation of bleeding time correction and VIIIvwF levels in D. K. differs from the findings reported by Ratnoff and co-workers for two patients with VWD. In each of these individuals the bleeding time remained long even though VIIIAHF and VIIIAGN rose to normal levels and the platelets aggregated normally with ristocetin (44, 45) . These contrasting observations indicate the need for further careful studies of the relationship of the bleeding time and VIIIVWF levels in VWD.
The apparent in vivo difference in the VIIIAHF response from that of the VIIIAGN and VIIIvwF in patient C. P. (Fig. 4 ) must be interpreted with caution. Although it is possible that epinephrine has a differential stimulatory effect on three separate entities, the nature of these assays makes it impossible to compare the different components of the Factor VIII complex in any direct way. Each property is quantified by reference to a normal plasma pool standard and only relative concentrations can be measured. If the normal plasma standard contains different numbers of molecules of the components of the Factor VIII complex, addition of material which has the same number of molecules of each component would cause variable changes in the values measured in the three assays. The different responses of the three properties would be most apparent if only a small proportion of the Factor VIII complexes in normal plasma had VIIIAHF activity. If this were the case, the postinfusion changes in VIIIAHF would be more striking if fully active molecules were released from endothelial cells by epinephrine stimulation. A similar differential response of VIIIAHF and VIIIAGN has been reported by Ruggeri and co-workers in their studies of a synthetic analogue of vasopressin. The basis for this differential response in plasma assay values was not discussed in their preliminary report (46) .
We do not know how epinephrine causes changes in Factor VIII levels. Although this drug may effect the release of Factor VIII storage from sites, it is also possible that it may affect the Factor VIII molecule, either directly or indirectly. Transient thrombin generation, for example, would increase VIIIAHF without affecting VIIIAGN or VIIIvwF, i.e., VIIIAHF could be "activated" (46) (47) (48) (49) . Postinfusion VIIIAHF appears to be very large, however, (Fig. 6) , an observation which is not consistent with the changes in the sedimentation and chromatographic properties which have been described for thrombin-activated Factor VIII (50, 51). Further assessment of the possible role of thrombin generation during epinephrine infusion and of the properties of the "stimulated AHF" are in progress.
The pattern of Factor VIII related measurements after epinephrine infusion in C. P. (Fig. 4) , normal VIIIAHF with very low VIIIVwF and VIIIAGN, is similar to that which has been identified after plasma or cryoprecipitate infusion in VWF (9, 10). Material which has VIIIAHF, and which has very low VIIIAGN and VIIIvwF levels, has also been identified in in vitro studies in which Factor VIII is exposed to high ionic strength buffers (32, 47) . Although this similarity is of great interest, its significance is uncertain. Since these studies, it is important to recognized the inherent problems in determining VIIIAHF size. It is possible that the properties of postinfusion VIIIAHF are modified by the association of low molecular weight material with the larger components of the factor VIII complex which are present in these plasmas. It is also possible that there is aggregation of "stimulated VIIIAHFi" during storage and/or in vitro analysis.
The different patterns of response to epinephrine in these patients may correspond to differences in the molecular defects which are responsible for VWD. In the most severe form of the disease (patient H. E.), no Factor VIII could be detected, even after epinephrine stimulation; this may represent an absolute defect in synthesis. Reduced but measurable quantities of the components of the Factor VIII complex are present in patients with mild and moderate VWD. The increases detected after epinephrine stimulation suggest that some control mechanisms are present in these individuals, however, and that they are susceptible to pharmacologic modification. The relationship of this modification to possible treatment of VWD remains to be determined.
